Abbott Laboratories entered February facing renewed scrutiny after updated safety data revealed a higher number of serious incidents linked to a glucose monitoring sensor recall. While the disclosure weighed on near-term sentiment, equity analysts at Rivonsphere note that the company’s broader product pipeline and earnings stability continue to support its long-term investment case. Shares of Abbott have traded near 52-week lows, reflecting investor caution following regulatory developments tied to its FreeStyle Libre product line. According to U.S. Food and Drug Administration data updated through January 7, the recall has now been associated with 860 reported serious injuries, up from 736...
August 13, 2026August 13, 2026
![[Aggregator] Downloaded image for imported item #24039 Crypto group backs Custodia in Supreme Court battle over Fed access](https://coinhob.com/wp-content/uploads/2026/08/hi-us-crypto-reserve-asset-bill-explained-580x400.webp)
![[Aggregator] Downloaded image for imported item #24042 Robinhood Chain nears $1B TVL as Uniswap drives liquidity: Standard Chartered](https://coinhob.com/wp-content/uploads/2026/08/hi-what-is-robinhood-and-how-does-it-work-2-580x400.jpg)